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A B S T R A C TObjective: To estimate the cost-effectiveness of a trial of labor after
one previous cesarean (TOLAC) when incorporating long-term events
and outcomes. Methods: A Markov model comparing TOLAC with
elective repeat cesarean delivery (ERCD) was developed for a hypo-
thetical cohort with no contraindication to a TOLAC. Women were
selected from a prospective study to derive probability estimates for
potential events through three subsequent pregnancies. Probabilities
for cerebral palsy and stress urinary incontinence, cost data, and
quality-adjusted life-years (QALYs) were obtained from the literature.
The primary outcome was cost-effectiveness measured as the mar-
ginal cost per QALY gained, with a $50,000 threshold per QALY used to
deﬁne cost-effectiveness. Results: The TOLAC strategy dominated the
ERCD strategy at baseline, with $164.2 million saved and 500 QALYs
gained per 100,000 women. The model was sensitive to six variables:
the probability of uterine rupture and successful TOLAC amongsee front matter Copyright & 2013, International S
r Inc.
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ndence to: Sharon A. Gilbert, The George Washingwomen with no prior vaginal delivery, the frequency of stress urinary
incontinence, and the costs of failed TOLAC, successful TOLAC, and
ERCD. When the probability of TOLAC success was at the base value,
67.2%, TOLAC was preferred if the probability of uterine rupture was
3.1% or less. When the probability of uterine rupture was at the base
value, 0.8%, the TOLAC strategy was preferred as long as the
probability of success was 47.2% or more. Probabilistic sensitivity
analysis conﬁrmed the base-case analysis. Conclusions: Under base-
line circumstances, TOLAC is less expensive and more effective than
an ERCD when considering long-term consequences when the like-
lihood of success is 47.2% or more.
Keywords: accreta, cost-effectiveness, elective repeat, trial of labor.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In the United States, approximately 1 out of every 5 women, or
almost 300,000 women per year, planning the delivery of her
second child has had a prior cesarean delivery and is therefore
faced with the choice of whether to attempt a trial of labor [1,2].
The ramiﬁcations of this decision on maternal and infant out-
comes have been reviewed in several articles and summarized in
the Agency for Healthcare Research and Quality (AHRQ) evidence
report and technology assessment, which concluded that “vagi-
nal birth after a previous cesarean is a reasonable and safe choice
for the majority of women with prior cesarean” [3]. To adequately
counsel women, both the short-term and the long-term maternaland infant effects of this decision must be considered. The
downstream effects include not only adverse perinatal outcomes
from the index delivery, such as cerebral palsy (CP), but adverse
outcomes in future pregnancies, such as placenta previa and
accreta.
Previous decision analyses have compared trial of labor after a
previous cesarean (TOLAC) with elective repeat cesarean delivery
(ERCD), but these have been limited in their inclusion of inputs
and the incorporation of long-term health consequences related
to the initial delivery approach [4–8]. For example, three analyses
provided the outcome of the initial decision without considering
further pregnancies [4–6], and another did not take into consid-
eration patient preferences [7]. A decision model comparing theseociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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consequences throughout reproductive life, but did not include
costs, preferences, or infant outcomes [8].
The present cost-effectiveness analysis was undertaken to
incorporate relevant long-term outcomes and to determine the
future health and economic consequences of choosing a TOLAC
as opposed to an ERCD among women with one previous
cesarean.Methods
We developed a decision analytic model comparing a TOLAC with
an ERCD for a hypothetical cohort of 100,000 women who had no
contraindication to a TOLAC and whose only previous delivery
was through a low transverse cesarean incision. To model down-
stream effects from this initial decision, a Markov model was
developed to account for potential events related to this initial
choice throughout a woman’s life. This analysis was based on the
societal perspective, incorporating all health outcomes andTOLAC or rep
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Fig. 1 – Flowchart illustrates the development of the index pregn
disproportion; ERCD, elective repeat cesarean delivery; FTP, failu
pPROM, premature rupture of the membranes; TOLAC, trial of laeconomic costs regardless of who experienced the outcome or
paid the costs [9]. The primary outcome was cost-effectiveness,
measured as the marginal cost per quality-adjusted life-year
(QALY) gained, with a marginal cost per QALY ratio of less than
$50,000 (a frequently used threshold in the United States) used to
deﬁne cost-effectiveness [10].
The decision tree was developed by using TreeAge Pro 2012
(TreeAge Software, Inc., Williamstown, MA). Probabilities for the
decision tree were obtained primarily from data collected from
1999 through 2002 in a registry (the Cesarean Registry) by
institutions of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Maternal-Fetal Medicine
Units Network. Nineteen clinical centers throughout the United
States participated in this observational study, in which data
were collected on all women with a prior cesarean delivery. The
study was approved by the institutional review board of each
participating center where study personnel abstracted data from
patient charts under a waiver of informed consent. Further detail
on the Cesarean Registry can be obtained from previously
































ancy study groups. CD, cesarean delivery; CPD, cephalopelvic
re to progress; LTCS, low-transverse cesarean section;
bor after a previous cesarean.
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The initial decision represented a woman’s approach to delivery:
either a TOLAC or an ERCD (Fig. 1). Women who were eligible for
this choice had a singleton, term vertex gestation, and one prior
low transverse incision without a prior vaginal delivery (n ¼
14,682). A gestation was considered term if delivery occurred at or
beyond 37 weeks’ gestation. An ERCD was deﬁned as a cesarean
delivery without any indication other than the prior cesarean.
Thus, women who had a repeat cesarean for indications such as
placenta previa or active herpes were excluded (n ¼ 686). To
ensure that women who underwent ERCD truly had no indication
for cesarean other than their choice, those who reported to have
a cesarean that was elective but who had an additional reported
indication implying that this was not the case (i.e., cephalopelvic
disproportion, failure to progress, cord prolapse, nonreassuring
tracing or abruption) were excluded (n ¼ 210). Also, women were
ineligible for the cohort if they had a scheduled cesarean prior to
39 weeks without spontaneous labor or premature rupture of
membranes given that elective delivery prior to 39 weeks is
associated with known adverse outcomes unrelated to the mode
of delivery (n ¼ 2566) [13]. Women with induced labor were also
excluded because this intervention has been associated with a
lower probability of success and a higher probability of uterine
rupture, and is not a probabilistic possibility but a choice that a
woman and her provider can make (n ¼ 1682) [14,15]. Women
carrying fetuses with congenital malformations (i.e., trisomy,
clubbed foot, neural tube defect) were removed because these
conditions, unrelated to the mode of delivery, could inﬂuence the
newborn outcome (n ¼ 84). This process left 9454 women for
analysis, of whom 4253 (45.0%) had a TOLAC and 5201 (55.0%) had
an ERCD. The maternal and infant outcomes in the decision tree
were contingent on the mode of delivery (i.e., vaginal delivery,
cesarean delivery, or delivery in the context of uterine rupture).Fig. 2 – Example of the TOLAC 2 arm of the decision tree. HIE, h
syndrome; TOLAC, trial of labor after a previous cesarean; TTN,Subsequent health states were determined for future pregnan-
cies, with the assumption that for all modes of delivery after two
births, 22% of the women will have a third child, and after three
births, 14% of the women will have a fourth child [16]. In the
model, those women who experienced a successful TOLAC were
potentially eligible for another TOLAC. Women who initially chose
an ERCD, or who experienced a cesarean or uterine rupture during
their chosen TOLAC, underwent an indicated repeat cesarean in
subsequent pregnancies. The cycle length between each preg-
nancy was 2 years, representing the average interval between
childbearing, whereas other health states had a 1-year cycle
length. Maternal age at the beginning of the Markov model was
assumed to be 28 years, the median maternal age of women in the
Cesarean Registry entering the model. The model was terminated
after 78 years, representing the life expectancy at birth of 77.9
years in 2007 [17] and when more than 92% of the infants entered
the death state. The maternal and infant branches of the tree were
considered to be independent events. Figure 2 shows as an
example the TOLAC 2 health state, representing women under-
going a TOLAC with a prior vaginal delivery.
Maternal and Infant Probabilities and Outcomes
Maternal and infant probabilities for these subsequent health
states were obtained on the basis of data from the Cesarean
Registry that accounted for the mode of delivery, the number of
prior cesareans, and the presence of prior vaginal deliveries. In
addition, the model accounted for the chance in subsequent
pregnancies that a woman developed indications for a cesarean
(e.g., breech presentation or active herpes lesion), or that a
placenta previa and/or accreta occurred (Tables 1–5). The ranges
used in sensitivity analysis were obtained from the 95% Blyth-
Still-Casella binomial conﬁdence intervals (from StatXact, Cytel
Inc., Cambridge, MA) on the basis of the proportion of eventsypoxic ischemic encephalopathy; RDS, respiratory distress
transient tachypnea of the newborn.







Baseline Range Baseline Range Baseline Range Baseline Range
TOLAC 1
Rupture 32 3.13 0.160–16.12 15.63 6.37–31.89 0 0–10.89 12.5 4.39–28.15
Failed
TOLAC
1385 0.217 0.059–0.607 1.23 0.717–1.95 1.30 0.811–2.01 7.80 6.46–9.31
Successful
TOLAC
2835 0 0–0.122 0 0–0.122 0.035 0.002–0.194 1.76 1.32–2.31
TOLAC 2 and 3
Indicated
repeat
454 0.220 0.011–1.22 0.661 0.180–1.86 0.661 0.180–1.86 5.51 3.60–7.90
Rupture 47 12.77 5.71–24.51 14.89 6.76–28.26 2.13 0.109–10.70 10.64 4.29–22.67
Failed
TOLAC
905 0.332 0.090–0.931 0.553 0.218–1.27 0.995 0.495–1.82 7.62 6.03–9.49
Successful
TOLAC
7095 0.127 0.063–0.240 0.014 0.001–0.077 0.042 0.012–0.118 0.691 0.511–0.908
ERCD 5199 0.231 0.129–0.390 0.231 0.129–0.390 0.846 0.616–1.12 1.67 1.34–2.06
IR-2CDNPV 6148 0.342 0.212–0.521 0.407 0.273–0.590 1.30 1.03–1.61 2.47 2.10–2.89
IR-3CDNPV 1728 1.22 0.754–1.82 0.984 0.574–1.56 1.74 1.17–2.46 2.37 1.71–3.17
IR-2CDPV 1184 0.676 0.292–1.30 0.760 0.378–1.41 1.35 0.815–2.14 2.96 2.07–4.04
Notes. Data presented as percentage; all data from the Cesarean Registry. Data were missing for one woman in the TOLAC 1, successful TOLAC
group and two women in the ERCD group.
ERCD, elective repeat cesarean delivery; IR-2CDNPV, indicated repeat cesarean with 2 prior cesareans and no prior vaginal delivery;
IR-3CDNPV, indicated repeat cesarean with 3 prior cesareans and no prior vaginal delivery; IR-2CDPV, indicated repeat cesarean with 2 prior
cesareans and one or more prior vaginal deliveries; TOLAC, trial of labor after a previous cesarean.
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rupture have previously been shown to be variables to which
the results of decision analytic models of TOLAC are sensitive,
these two variables were varied across a range (0%–5.0%) wider
than that which would have been derived from the data
set alone.
The maternal outcomes that were considered included endo-
metritis (clinical diagnosis of puerperal uterine infection in the
absence of ﬁndings suggesting another source), wound compli-
cation (seroma, hematoma, or infection), operative injury (broad
ligament hematoma, cystotomy, or bowel or ureteral injury),
peripartum hysterectomy, uterine rupture (disruption or tear of
the uterine muscle and visceral peritoneum or a uterine muscle
separation with extension to adjacent structures), placenta pre-
via, placenta accreta, thromboembolism, and maternal death. All
probabilities except for the ﬁnal two outcomes were obtained
from the Cesarean Registry. Because of the rarity of thromboemb-
olism and maternal death, these probabilities were estimated
from the literature [3,19]. Stress urinary incontinence (SUI) was
also incorporated into the model and estimated, from the
literature, as the marginal increase in long-term persistent SUI
for TOLAC compared with ERCD to the end of life [18]. Because
the data demonstrating this long-term increase have been con-
sidered inconclusive, these probabilities were not included in the
base-case scenario, but in the sensitivity analysis [21].
Neonatal outcomes that were evaluated were transient
tachypnea of the newborn (TTN), respiratory distress syndrome
(RDS), infection (i.e., suspected or conﬁrmed sepsis), acidemia
(arterial cord pH o7.0), hypoxic ischemic encephalopathy (HIE),
and neonatal death. Because CP could occur as a long-term
consequence of an event (HIE) at the time of delivery, the
probability of CP was incorporated in the model by estimating,
from the literature, that 12% of the infants with HIE would
ultimately be diagnosed with CP [22].Costs
With the exception of CP and SUI, the following costs, based on
the mode of delivery, were incorporated into the model: hospital,
obstetrician, pediatrician, anesthesiologist, and maternal and
caregiver opportunity costs. A summary of these costs by the
mode of delivery and outcome is provided in Table 6. Further
detail regarding the basis for these costs is provided in the
Supplemental Materials (S1-S2) found at http://dx.doi.org/10.
1016/j.jval.2013.06.014. Hospital costs were obtained from the
2009 AHRQ’s Healthcare Cost and Utilization Project Nationwide
Inpatient Sample (HCUPnet), a nationwide database of hospital
inpatient stays containing approximately 95% of all hospital
discharges in the United States [23]. These costs represent direct
and indirect hospital costs. Obstetrician and pediatrician costs
were obtained from the 2010 Current Procedural Terminology
from the American Medical Association [24]. Because the
Cesarean Registry did not contain data that would allow estima
tion of anesthesia costs, these costs were derived from the
literature [4]. Maternal and caregiver postpartum opportunity
costs were derived from the Bureau of Labor Statistics by using
the 2009 median hourly wage and salary averages for women 25
to 34 years old and for all individuals 16 years and older,
respectively [25]. Because the costs associated with maternal
and infant death are hard to quantify, as these events occur in
such a large variety of circumstances, a range of $0 to $1 million
was used, with hospital baseline estimates of $20,000 and
$50,000, respectively, approximating a high hospital cost outcome
such as hysterectomy or HIE. For CP, hospital costs after delivery
were estimated as twice the base cost of HIE, with the addition of
approximately $9,000 for pediatrician fees and $23,800 of direct
and indirect costs per year for the next 49 years [26–28]. Costs
associated with SUI were obtained from the literature and
accorded a yearly cost of $400, with a range of $0 to $1600 [29].
All costs are presented in 2009 US dollars, with adjustments for
Table 2 – Other maternal probability estimates.
Outcome Baseline Range Reference
Likelihood of third pregnancy 0.22 0.11–0.88 [16]
Likelihood of fourth pregnancy 0.14 0.07–0.56 [16]
Rupture
One prior low-transverse incision 0.752 0–5.0 CR
One prior CD, ≥1 prior vaginal delivery 0.378 0–5.0 CR
Successful TOLAC
One prior low-transverse incision 67.19 20.0–1.0 CR
One prior CD, ≥1 prior vaginal delivery 88.69 20.0–1.0 CR
Indicated repeat
One prior CD, ≥1 prior vaginal delivery 6.01 5.53–6.52 CR
Stress urinary incontinence 0 0–22.0 [18]
Thromboembolism
Successful TOLAC* 0.0445 0.0358–0.0530 [19]
Rupture, failed TOLAC, ERCD, indicated repeat* 0.178 0.143–0.212 [19]
Maternal death
Failed TOLAC for TOLAC 1† 0.0040 0.0008–0.0201 [3]
Successful TOLAC for TOLAC 1† 0.0008 0.0002–0.0040 [3]
Rupture for TOLAC 1† 0.0081 0.0017–0.0403 [3]
ERCD† 0.0096 0.0021–0.0432 [3]
Failed TOLAC and indicated repeat for TOLAC 2 and 3‡ 0.0104 0.0025–0.0425 [3]
Successful TOLAC for TOLAC 2 and 3‡ 0.0030 0.0007–0.0122 [3]
Rupture for TOLAC 2 and 3‡ 0.0209 0.0049–0.0851 [3]
Note. Data presented as percentage and represent conditional probabilities given prior mode of delivery.
CD, cesarean delivery; CR, data from the Cesarean Registry; ERCD, elective repeat cesarean delivery; TOLAC, trial of labor after a previous
cesarean.
 Thromboembolism rate for cesarean delivery four times successful TOLAC [19].
† From term maternal death studies [3]. Assumption risk ﬁve times higher for failed TOLAC compared with successful TOLAC, failed TOLAC
33% of all TOLAC, rupture risk twice failed TOLAC.
‡ From all maternal death studies [3]. Assumption risk 3.5 times higher for failed TOLAC compared with successful TOLAC, failed TOLAC 11%
of all TOLAC, rupture risk twice failed TOLAC.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 5 3 – 9 6 4 957inﬂation, when needed, according to the medical care component
of the Consumer Price Index [30]. In sensitivity analysis, because
of the lack of standard errors for most values, the majority of
costs ranged from 50% to 400% of the base-case estimate. For
maternal and well-infant discharge, the upper limit of the range
was set at 150% because it was assumed that costs above this
range would imply an adverse outcome. Although the ranges
included values that appeared beyond plausible in some cases,
such a wide range ensured that threshold analyses could be
judiciously performed [31].
Quality of Life
Disutilities or utility decrements were assigned on the basis of
the literature (Table 7) [4,32–34]. All women experiencing pla-
centa accreta were assigned the hysterectomy disutility. Those
infants who experienced infant death, CP, and HIE were assigned
disutilities of 0, 0.44, and 0.75, respectively. QALYs were deter-
mined on the basis of utilities and life expectancy. It was
assumed that the mode of delivery per se did not alter maternal
or neonatal life expectancy, which was estimated by using 2007
life table estimates [17]. For infants with CP, however, a life
expectancy of 50 years was assumed [27].
Sensitivity Analyses
To test the robustness of the results obtained from the base-case
model, sensitivity analyses were performed. One-way sensitivity
analysis was conducted on all probabilities, costs, and QALYs by
varying one variable at a time from the low to the high value in
its range, while holding other variables ﬁxed. As recommendedby the United States Panel on Cost Effectiveness in Health
and Medicine, all costs and QALYs were discounted at 3%
annually in the base case, with a range of 0% to 7% tested in
sensitivity analysis [35]. Multivariable sensitivity analysis
was also conducted by varying more than one probability at a
time. This included probabilistic sensitivity analysis (PSA) using
Monte Carlo simulation with 10,000 iterations to determine how
often the base-case strategy was preferred. Simulation was
conducted by using the beta or uniform distribution for the
probabilities where appropriate and the gamma distribution
for costs.Results
Base-Case Scenario Analysis
The base-case analysis revealed that for a hypothetical cohort of
100,000 women whose ﬁrst birth was a low-transverse cesarean,
the choice of a TOLAC resulted in 80,229 fewer cesareans as well
as fewer cases of the long-term maternal outcomes hysterectomy
(271), placenta previa (93), placenta accreta (80), and maternal
death (10) (Table 8). Conversely, TOLAC was associated with
816 additional uterine ruptures, as well as the long-term adverse
neonatal outcomes of infant death (111), HIE (76), and
CP (9). Overall, the TOLAC strategy was dominant because it
was both less expensive and more effective than the ERCD
strategy, with $164.2 million and 500 QALYs saved per 100,000
women (Table 9).
Table 3 – Previa and accreta probability estimates.
Outcome n/Denominator Baseline Range Reference
Previa (with or without accreta)
One prior CD 254/35,420 0.717 0.632–0.810 CR
Two prior CD 77/8,335 0.924 0.730–1.15 CR
Three prior CD 52/2,217 2.35 1.76–3.03 CR
Accreta
Previa, one prior CD 28/254 11.02 7.45–15.33 CR
Previa, two prior CD 30/77 38.96 28.05–50.75 CR
Previa, three prior CD 31/52 59.62 45.10–72.99 CR
Maternal death
Previa only* NA 0.0104 0.0025–0.0425 [3]
Accreta and previa 1/89 1.12 0.058–5.52 CR
Thromboembolism
Previa only NA 0.178 0.143–0.212 [19]
Accreta and previa NA 0.178 0.143–0.212 [19]
Hysterectomy
Previa only, one prior CD 5/226 2.21 0.876–4.84 CR
Previa only, two prior CD 7/47 14.89 6.76–28.26 CR
Previa only, three prior CD 4/20 20.00 7.14–41.11 CR
Operative injury
Previa only 2/294 0.680 0.121–2.38 CR
Accreta and previa 17/89 19.10 12.08–28.10 CR
Wound complication
Previa only 5/294 1.70 0.672–3.78 CR
Accreta and previa 2/89 2.25 0.401–7.33 CR
Endometritis
Previa only, one prior CD 7/226 3.10 1.46–6.20 CR
Previa only, two prior CD 2/47 4.26 0.761–13.94 CR
Previa only, three prior CD 1/20 5.00 0.256–23.06 CR
Accreta and previa 2/89 2.25 0.401–7.33 CR
Note. Data presented as percentage and represent conditional probabilities given prior mode of delivery or outcome.
CD, cesarean delivery; CR, data from the Cesarean Registry; NA; not applicable.
 From all maternal death studies [3].
Table 4 – Infant outcome probability estimates.
Mode of delivery n Neonatal death HIE Sepsis
Baseline Range Baseline Range Baseline Range
TOLAC 1
Rupture 32 3.13 0.160–16.12 3.13 0.160–16.12 18.75 8.50–34.74
Failed TOLAC 1384 0.072 0.004–0.397 0.072 0.004–0.397 7.08 5.79–8.51
Successful TOLAC 2836 0 0–0.122 0.035 0.002–0.194 3.81 3.13–4.56
TOLAC 2 and 3
Indicated repeat 544 2.21 1.24–3.75 – – 20.04 16.75–23.51
Rupture 48 2.08 0.107–10.47 6.25 1.73–16.95 29.17 16.95–43.21
Failed TOLAC 907 0.882 0.382–1.70 0.221 0.039–0.765 13.45 11.30–15.84
Successful TOLAC 7096 0.90 0.70–1.15 0 0–0.049 5.95 5.41–6.52
ERCD 5201 0 0–0.066 – – 2.86 2.43–3.34
IR-2CDNPV 6203 0.580 0.408–0.796 – – 7.38 6.75–8.06
IR-3CDNPV 1767 0.792 0.460–1.29 – – 10.41 9.03–11.91
IR-2CDPV 1196 1.25 0.704–2.05 – – 12.21 10.40–14.17
Notes. Data presented as percentage and represent conditional probabilities given prior mode of delivery; all data from the Cesarean Registry.
Data were missing for one infant in the TOLAC 1, failed TOLAC group.
HIE, hypoxic ischemic encephalopathy; ERCD, elective repeat cesarean delivery; IR-2CDNPV, indicated repeat cesarean with 2 prior cesareans
and no prior vaginal delivery; IR-3CDNPV, indicated repeat cesarean with 3 prior cesareans and no prior vaginal delivery; IR-2CDPV, indicated
repeat cesarean with 2 prior cesareans and one or more prior vaginal deliveries; TOLAC, trial of labor after a previous cesarean.
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Table 5 – Infant outcome probability estimates.
Mode of delivery n RDS TTN Acidemia
Baseline Range Baseline Range Baseline Range
TOLAC 1
Rupture 32 0 0–9.47 0 0–9.47 9.38 2.60–23.70
Failed TOLAC 1384 1.01 0.588–1.65 1.81 1.21–2.63 0.578 0.250–1.11
Successful TOLAC 2836 0.670 0.404–1.04 0.741 0.459–1.12 0.071 0.013–0.244
TOLAC 2 and 3
Indicated repeat 544 6.07 4.21–8.36 2.94 1.78–4.68 0.368 0.065–1.28
Rupture 48 2.08 0.107–10.47 0 0–6.64 12.50 5.59–24.03
Failed TOLAC 907 2.54 1.67–3.74 1.87 1.10–2.98 0.662 0.289–1.38
Successful TOLAC 7096 1.02 0.795–1.28 0.832 0.634–1.06 0.085 0.037–0.183
ERCD 5201 0.461 0.296–0.681 1.31 1.02–1.65 0.250 0.133–0.421
IR-2CDNPV 6203 1.76 1.45–2.11 1.94 1.61–2.30 0.306 0.185–0.475
IR-3CDNPV 1767 2.72 2.01–3.56 2.21 1.57–3.00 0.396 0.186–0.782
IR-2CDPV 1196 2.34 1.61–3.34 1.25 0.704–2.05 0 0–0.289
Notes. Data presented as percentage and represent conditional probabilities given prior mode of delivery; all data from the Cesarean Registry.
Data were missing for one infant in the TOLAC 1, failed TOLAC group.
ERCD, elective repeat cesarean delivery; IR-2CDNPV, indicated repeat cesarean with 2 prior cesareans and no prior vaginal delivery; IR-
3CDNPV, indicated repeat cesarean with 3 prior cesareans and no prior vaginal delivery; IR-2CDPV, indicated repeat cesarean with 2 prior
cesareans and one or more prior vaginal deliveries; RDS, respiratory distress syndrome; TOLAC, trial of labor after a previous cesarean; TTN,
transient tachypnea of the newborn.
Table 6 – Cost estimates by mode of delivery.
Outcomes Uterine rupture Failed TOLAC Successful TOLAC ERCD/indicated
repeat*
Baseline Range Baseline Range Baseline Range Baseline Range
Maternal
Death 27.9 0–1000.0 27.9 0–1000.0 24.1 0–1000.0 27.41 0–1000.0
Thromboembolism 19.1 9.6–76.5 18.4 9.2–73.5 13.3 6.7–53.3 16.61 8.3–66.4
Hysterectomy 20.4 10.2–81.5 19.6 9.8–78.6 14.6 7.3–58.4 17.9 8.9–71.5
Operative injury 16.4 8.2–65.6 15.7 7.8–62.6 10.6 5.3–42.5 13.9 6.9–55.6
Wound
complication
18.1 9.0–72.3 17.3 8.7–69.4 12.3 6.2–49.2 15.6 7.8–62.3
Endometritis 18.2 9.1–73.0 17.5 8.8–70.0 12.5 6.2–49.9 15.7 7.9–63.0
Well (no adverse
outcome)
13.9 6.9–20.8 13.1 6.6–19.7 8.1 4.0–12.1 11.4 5.7–17.0
Infant
Death 52.2 0–1000.0 52.2 0–1000.0 52.2 0–1000.0 52.2 0–1000.0
CP, acute care at
birth
82.4 41.2–329.7 82.4 41.2–329.7 82.4 41.2–329.7 NA NA
CP, ongoing care
per year
23.8 11.9–95.1 23.8 11.9–95.1 23.8 11.9–95.1 NA NA
HIE 40.9 20.4–163.5 40.9 20.4–163.5 40.9 20.4–163.5 40.9 20.4–163.5
Sepsis 8.6 4.3–34.2 8.6 4.3–34.2 8.6 4.3–34.2 8.6 4.3–34.2
RDS 25.9 12.9–103.5 25.5 12.7–101.9 25.5 12.7–101.9 25.5 12.7–101.9
TTN 9.1 4.5–36.3 8.7 4.3–34.6 8.7 4.3–34.6 8.7 4.3–34.6
Acidemia 7.7 3.9–30.9 7.3 3.7–29.3 7.3 3.7–29.3 7.3 3.7–29.3
Well (no adverse
outcome)
0.9 0.5–1.4 0.9 0.4–1.3 0.9 0.4–1.3 0.9 0.5–1.3
Note. Currency in dollars ($thousands).
CP, cerebral palsy; ERCD, elective repeat cesarean delivery; HIE, hypoxic ischemic encephalopathy; NA, not applicable; RDS, respiratory distress
syndrome; TOLAC, trial of labor after a previous cesarean; TTN, transient tachypnea of the newborn.
 For maternal outcomes placenta previa and accreta in the indicated repeat groups, $5064 and $8561 in additional costs applied, respectively.
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Table 7 – Disutility estimates by mode of delivery or outcome.
Mode of delivery/outcome Disutility Disutility days
Baseline Range Baseline Range Reference
Maternal 0 0–0.5 All All Assumed
ERCD/indicated repeat 0.45 0.25–0.65 21 14–180 [4]
Uterine rupture 0.49 0.29–0.69 21 14–180 [4]
Failed TOLAC* 0.47 0.27–0.67 21 14–180 [4]
Successful TOLAC 0.35 0.15–0.55 7 2–42 [4]
Hysterectomy† 0.49 0.29–0.69 21 14–180 [4,32]
Stress urinary incontinence 0.19 0–0.29 All All [33]
Cerebral palsy 0.44 0.26–0.61 All All [34]
HIE 0.75 0.35–0.95 42 14–180 Assumed
Infant 0 0–0.75 All All Assumed
ERCD, elective repeat cesarean delivery; HIE, hypoxic ischemic encephalopathy; TOLAC, trial of labor after a previous cesarean.
 Extrapolated from Chung et al. [4], midway between ERCD and rupture.
† Blend of Harris et al. [32] and Chung et al. [4] at 55% and 45%, respectively, to represent the proportion of women with a hysterectomy who
would and would not have desired another pregnancy. For Chung et al. [4], assumed the disutility and disutility days in the table and from
Harris et al. [32], disutilities of 0.31 (0.14–0.48) until age 50 y result in a disutility and range for ﬁrst 2 years of 0.35 (0.15–0.55) and subsequently
0.17 (0.08–0.26) until age 50 y.
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These results were robust to all changes except for six variables as
determined by one-way sensitivity analysis. These variables and their
threshold values were the probability of uterine rupture during TOLAC
for women without a prior vaginal delivery (3.1%), the probability of
successful TOLAC for women without a prior vaginal delivery (46.4%),
the cumulative increase in frequency of SUI among women under-
going a TOLAC (0.8%), and the cost of failed TOLAC ($19,246), the cost
of successful TOLAC ($10,485), and the cost of ERCD ($9,420).
Bivariable analysis on the probability of uterine rupture and
successful TOLAC in women without a prior vaginal delivery
indicated that when the probability of uterine rupture was at 0%,Table 8 – Maternal and infant outcomes per 100,000 wom
Outcome Second child (index pregnancy) T
TOLAC ERCD TO
Deliveries 100,000 100,000 21
Cesarean deliveries 33,315 100,000 9
Uterine rupture 752 0
Maternal death 2 10
Thromboembolism 89 178
Hysterectomy 94 231
Operative injury 513 230
Wound infection 439 841
Endometritis 3,716 1,645
Previa alone 0 0
Accreta 0 0
Infant death 47 0
Cerebral palsy 9 0
HIE 69 0




ERCD, elective repeat cesarean delivery; HIE, hypoxic ischemic encephalo
a previous cesarean; TTN, transient tachypnea of the newborn.the TOLAC strategy was preferred if the probability of success was
40.0% or more. When the probability of uterine rupture was at the
base value, 0.8%, TOLAC was preferred if the probability of success
was 47.2% or more. When the probability of uterine rupture was set
at 1.5% and 3.0%, TOLAC was preferred if the probability of success
was 53.6% and 67.2% or more, respectively. When the probability of
success was set at the base value, 67.2%, TOLAC was preferred when
the probability of uterine rupture was 3.1% or less.
The sensitivity of the three SUI variables was also assessed.
For example, when the probability, cost, and disutility of SUI were
set at the upper limit (22.0%, $1600, and 0.29, respectively), ERCD
was preferred because the TOLAC strategy cost $701.1 million and
156,400 QALYs more per 100,000 women. When the frequency ofen by mode of delivery.
hird child Fourth child Total
LAC ERCD TOLAC ERCD TOLAC ERCD
,979 21,947 3,065 3,049 125,044 124,996
,796 21,947 1,656 3,049 44,767 124,996
52 0 12 0 816 0
1 3 0 0 3 13
23 39 4 5 116 222
87 171 35 85 216 487
58 104 20 37 591 371
121 283 26 52 586 1,176
427 530 63 70 4,206 2,245
47 124 13 29 60 153
27 79 15 43 42 122
186 127 29 24 262 151
0 0 0 0 9 0
6 0 1 0 76 0
,648 1,610 277 315 6,899 4,785
311 356 54 74 1,101 878
265 385 39 58 1,317 1,710
43 60 6 10 318 309
pathy; RDS, respiratory distress syndrome; TOLAC, trial of labor after
Table 9 – Overall cost-effectiveness analysis results at 3% discount rate.




TOLAC 14,472 0 69.053 0 210
ERCD 16,113 1642 69.048 –0.005 233 –328,200 per
QALY
C, cost; E, effectiveness; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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TOLAC compared with ERCD, as suggested by Press et al. [18],
and the cost and disutility set at the base values ($400, 0.19),
ERCD was preferred. For 100,000 women, this strategy cost $56.0
million more but in contrast saved 50,900 QALYs, and therefore
resulted in an incremental cost per QALY of $1100. If the disutility
was set at 0.05, with the frequency set at the threshold (0.8%) and
the cost at the base value ($400), TOLAC was the preferred
strategy because ERCD cost $1566 more with increasing effective-
ness of 0.005, with an incremental cost-effectiveness ratio of
approximately $326,000. Moreover, with a disutility of 0.05,
TOLAC was preferred over the entire cost range ($0–$1,600) only
if the frequency of SUI was 1.8% or less.
PSA (Table 10) of the ﬁve sensitive variables (excluding the
frequency of SUI) resulted in TOLAC preferred 69.4%, 68.5%, and
68.0% of the time at cost-effectiveness thresholds of $100,000,
$50,000, and $25,000, respectively. When including the frequency
of SUI, TOLAC was preferred 2.9%, 5.0%, and 9.0% of the time.
When all the variables without SUI were subjected to PSA, TOLAC
was preferred 63.0%, 64.6%, and 65.7% of the time (Fig. 3). When all
variables were subjected to PSA, however, TOLAC was preferred
4.6%, 7.3%, and 11.8% of the time (Fig. 4). Changing the range of cost
variables to 50% to 150% did not appreciably change the results.Discussion
Under the base-case assumptions, for 100,000 women with one
prior low-transverse cesarean delivery, choosing to deliver a
second child by TOLAC was the most cost-effective strategy
when the future consequences of this decision were considered,




All variables without stress urinary incontinence
Six sensitive‡
Stress urinary incontinence§
All variables, costs 50%–400%
All variables, costs 50%–150%
ERCD, elective repeat cesarean delivery; TOLAC, trial of labor after a pre
 The probability, cost, and disutility of cerebral palsy.
† The probability of uterine rupture and successful TOLAC without a pr
TOLAC, and the cost of ERCD all without complications.
‡ The probability of uterine rupture and successful TOLAC without a pr
TOLAC, the cost of ERCD all without complications, and the total freque
§ The probability, cost, and disutility of stress urinary incontinence.upon prior analyses in several ways. First, our study incorporates
several maternal and infant long-term downstream outcomes,
such as placenta accreta and CP, that have not been assessed
simultaneously. The maternal and infant probabilities used to
inform the model were obtained mainly from an observational
study conducted to speciﬁcally answer questions related to the
mode of delivery after a previous cesarean. This allowed us to
uniquely identify cohorts of women that ﬁt speciﬁc criteria
throughout the reproductive life cycle to populate the model.
Moreover, whereas previous studies relied on cost data from a
select set of institutions, this analysis used cost data from the
AHRQ and the American Medical Association.
The present analysis demonstrated that although TOLAC was
cost-effective under the base-case assumptions, it was sensitive to
several variables that, if altered sufﬁciently, resulted in the
alternate strategy of ERCD being preferred. As in previous analy-
ses, the results were found to be sensitive to the probability of
uterine rupture and successful TOLAC. Speciﬁcally, when the
probability of TOLAC success was below 46%, TOLAC was no
longer cost-effective. In addition, the results were found to be
sensitive to the three cost variables for the mode of delivery. The
thresholds represented 18%, however, to almost 50% of the base
values, implying that these values would be unlikely to occur. Of
note, the results were affected by the addition of SUI. Because the
evidence for a marginal increase in the setting of TOLAC compared
with ERCD has been considered inconclusive by review panels,
this was investigated in sensitivity analysis [21]. This analysis
suggests that if TOLAC inﬂuences SUI by more than 0.8%, with a
cost of $400 and a disutility of 0.19 per year, the preferred strategy
changes to an ERCD. In contrast, it has been suggested that ERCD
may be associated with higher rates of childhood asthma and











ior vaginal delivery, the cost of failed TOLAC, the cost of successful
ior vaginal delivery, the cost of failed TOLAC, the cost of successful
ncy of stress urinary incontinence.
Fig. 3 – Cost-effectiveness acceptability curve for all variables without stress urinary incontinence, costs 50% to 400%. ERCD,
elective repeat cesarean delivery; TOLAC, trial of labor after a previous cesarean.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 5 3 – 9 6 4962marginal increase for incontinence in the TOLAC arm [36]. They
were not modeled here, however, as well because the scientiﬁc
evidence for these marginal effects is also considered insufﬁcient
and even less robust than that for incontinence [36,37].
A direct comparison with previous analyses comparing
TOLAC with ERCD is difﬁcult due to the different parameters
and model structures used. The Grobman et al. [7] life-cycle
model found that TOLAC would save $179 million per 100,000Fig. 4 – Cost-effectiveness acceptability curve for all variables, c
TOLAC, trial of labor after a previous cesarean.women; however, QALYs were not included in the analysis. The
analyses by Chung et al. [4], Gilbert et al. [5], and Fawsitt et al. [6],
which incorporated only the pregnancy immediately following
one prior cesarean, found the TOLAC strategy to be cost-effective.
Chung et al. [4] reported that ERCD would cost $112,023 per QALY
(no total QALYs were provided), whereas Gilbert et al. [5] reported
$138.6 million saved and 1703 QALYs gained. Fawsitt et al. [6]
found TOLAC to be the dominant base-case strategy, savingosts 50% to 400%. ERCD, elective repeat cesarean delivery;
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 5 3 – 9 6 4 963almost €221 million and 1615 QALYs per 100,000 women; how-
ever, no neonatal outcomes were incorporated in the analysis.
Pare et al. [8], without incorporating costs or QALYs in their
decision analysis, concluded that for a woman with a single prior
cesarean and planning only one more pregnancy, an ERCD was
preferred because it results in fewer hysterectomies. In contrast,
if several future pregnancies were desired, TOLAC was preferred
because of the overall reduction in cases of hysterectomy and
placenta accreta.
Limitations
The group of women modeled for the delivery of their second
child did not include those undergoing labor inductions given
that this is a choice and not a probabilistic occurrence. Instead, it
was predicated on women in spontaneous labor and included
probabilities of success and rupture with this type of labor after a
previous cesarean and without a prior vaginal delivery. The
sensitivity analysis, however, allows insight into whether induc-
tion would be cost-effective. The 2010 AHRQ evidence report
estimated the frequency for rupture for those induced at any
gestational age to be 1.5% [3]. Even at this frequency, the
preferred strategy changed to an ERCD only when the probability
of success was approximately less than 53%. Women induced
with a favorable cervix would be expected to have a chance of
success greater than that threshold. In addition, the model has
been developed to compare delivery approaches and not choices
in the timing of delivery (awaiting spontaneous labor for TOLAC
vs. scheduled cesarean delivery for ERCD). Thus, we have com-
pared the experience of TOLAC with repeat cesarean because this
is a choice that women may confront. Conversely, we have not
incorporated expectant management beyond 40 weeks into the
model because this is not a requirement of a TOLAC strategy but
a different choice altogether.
For feasibility and clarity, the maternal and infant probabil-
ities from the Cesarean Registry were based on a hierarchy and
therefore for several arms of the tree no more than one compli-
cation could be experienced by an individual. This effect, how-
ever, would be de minimus at best because 11 (0.12%) mothers and
220 (2.3%) infants in the primary cohort experienced more than
one outcome and thereby were too small in number to appropri-
ately include in the decision tree. In addition, women in the
rupture arm as well as the indicated repeat could experience
uterine rupture, placenta previa, or accreta with one other
maternal morbidity. This study collected data on hospital deliv-
eries with a gestational age greater than or equal to 20 weeks or
resulting in an infant weighing 500 g or more. Therefore, this
analysis was not able to incorporate any potential marginal
impact on fertility by mode of delivery, such as early miscarriages
and ectopic pregnancies. In addition, external validity may be
limited because the majority of the hospitals that participated in
the Cesarean Registry were teaching hospitals and may not be
representative of all settings in the United States health care
system.
Utilities relating to TOLAC and ERCD are very limited [37,38],
and although we feel that we used the best available sources
from the literature, they have their weaknesses. A majority of the
utilities came from Chung et al. [4] and their description of how
the utilities were collected includes the instrument used, the
Quality of Well-Being classiﬁcation system, but they do not
indicate how many people or what type (physicians or patients)
were included in data collection. In addition, the assigned
disutility days could potentially be short. We attempted to rectify
this by assigning a wide range to be tested in sensitivity analysis.
For example, Chung et al. assigned 21 disutility days to ERCD and
hysterectomy, whereas we incorporated a range of 14 to 180 days.
In addition, for a proportion of the hysterectomy population, weincorporated disutilities to represent women who would have
desired another pregnancy (Table 7). Moreover, the disutility
assigned to infants for CP was based on parental surveys of
children between 2 and 24 months of age with deafness and
various degrees of developmental delay rather than directly from
children themselves throughout their lifetime [34]. Ideally, a
population-based collection of utilities by mode of delivery would
be paramount.Conclusions
We found that when considering the future reproductive con-
sequences of a TOLAC compared with an ERCD to deliver a
second child, TOLAC is more cost-effective under a wide variety
of circumstances. This conclusion is sensitive to several variables
that must be considered in the cost-effective assessment; accord-
ingly, further efforts should be directed at research that will
determine the actual values for these variables.Acknowledgments
The authors thank the following core committee members who
participated in protocol development and coordination between
clinical research centers (Francee Johnson, BSN, and Julia Gold,
BSN/APN), data management (Sandra Meadows), and protocol/
data management and statistical analysis (Elizabeth Thom, PhD,
John C. Hauth, MD, and Dwight J. Rouse).
In addition to the authors, other members of the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development Maternal-Fetal Medicine Units Network are as
follows: The George Washington University Biostatistics Center—E.
Thom, H. Juliussen-Stevenson, M. Fischer, and L. Leuchtenburg;
Northwestern University—A. Peaceman, M. Socol, D. Gradishar, and
G. Mallett; The Ohio State University—J. Iams, F. Johnson,
S. Meadows, and H. Walker; University of Alabama at Birmingham
—D. Rouse, J. Hauth, A. Northen, and S. Tate; University of Texas
Southwestern Medical Center—K. Leveno, S. Bloom, J. Gold, and
D. Bradford; University of Utah—M. Belfort (Utah Valley Regional
Medical Center), F. Porter (Intermountain Healthcare), B. Oshiro
(McKay-Dee Hospital Center), K. Anderson (University of Utah
Health Sciences Center), and A. Guzman (McKay-Dee Hospital
Center); University of Pittsburgh—S. Caritis, K. Lain, M. Cotroneo,
D. Fischer, and M. Luce; Wake Forest University Health Sciences—P.
Meis, M. Harper, M. Swain, C. Mooreﬁeld, K. Lanier, and L. Steele;
Thomas Jefferson University—A. Sciscione, M. DiVito, M. Talucci,
and M. Pollock; Wayne State University—M. Dombrowski, G. Nor-
man, A. Millinder, C. Sudz, and B. Steffy; University of Cincinnati—
M. Miodovnik, T. Siddiqi, H. How, and N. Elder; Columbia University
—M. Miodovnik, F. Malone, M. D’Alton, V. Pemberton, V. Car-
mona, and H. Husami; Brown University—M. Carpenter, H. Silver,
J. Tillinghast, D. Catlow, and D. Allard; University of Miami—
M.J. O’Sullivan, G. Burkett, J. Gilles, J. Potter, F. Doyle, and
S. Chandler; University of Tennessee—W. Mabie and R. Ramsey;
University of Texas at San Antonio—D. Dudley, O. Langer, D. Con-
way, S. Barker, and M. Rodriguez; University of North Carolina—
K. Moise, K. Dorman, S. Brody, and J. Mitchell; The University of
Texas Health Science Center at Houston—L. Gilstrap, M. Day, M. Kerr,
and E. Gildersleeve; Case Western Reserve University-MetroHealth
Medical Center—P. Catalano, C. Milluzzi, B. Slivers, and C. Santori;
University of Chicago—A. Moawad, J. Hibbard, P. Jones, M. Ramos-
Brinson, M. Moran, and D. Scott; Eunice Kennedy Shriver National
Institute of Child Health and Human Development—D. McNellis,
K. Howell, and S. Tolivaisa; andMFMU Steering Committee Chair
(Vanderbilt University Medical Center)—S. Gabbe.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 5 3 – 9 6 4964Source of ﬁnancial support: None of the authors has a conﬂict
of interest. The project described was supported by grants from
the Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD) of the National Institutes of Health
(NIH) (HD21410, HD21414, HD27860, HD27861, HD27869, HD27905,
HD27915, HD27917, HD34116, HD34122, HD34136, HD34208,
HD34210, HD40500, HD40485, HD40544, HD40545, HD40560,
HD40512, and HD36801), and its contents are solely the respon-
sibility of the authors and do not necessarily represent the ofﬁcial
view of NICHD or the NIH.Supplemental Materials
Supplemental material accompanying this article can be found in the
online version as a hyperlink at http://dx.doi.org/10.1016/j.jval.2013.06.
014 or, if a hard copy of article, at www.valueinhealthjournal.com/
issues (select volume, issue, and article).
R E F E R E N C E S[1] MacDorman M, Declerq E, Menacker F. Recent trends and patterns in
cesarean birth after cesarean (VBAC) deliveries in the United States.
Clin Perinatol 2011;38:179–92.
[2] Martin JA, Hamilton BE, Ventura SJ, et al. Births: ﬁnal data for 2009. In:
National Vital Statistics Reports (Vol. 60, No. 1). Hyattsville, MD:
National Center for Health Statistics, 2011.
[3] Guise JM, Eden K, Emeis C, et al. Vaginal Birth After Cesarean: New
Insights. Evidence/Report Technology Assessment No. 191. (Prepared by
the Oregon Health & Science University Evidence-based Practice Center
under contract no. 290-2007-10057-I. AHRQ publication no. 10-E003).
Rockville, MD: Agency for Healthcare Research and Quality, 2010.
[4] Chung A, Macario A, El-Sayed YY, et al. Cost-effectiveness of a trial of
labor after previous cesarean. Obstet Gynecol 2001;97:932–41.
[5] Gilbert SA, GrobmanWA, Landon MB, et al. Cost-effectiveness of trial of
labor after previous cesarean in a minimally biased cohort. Am J
Perinatol 2013;30:11–20.
[6] Fawsitt CG, Bourke J, Greene RA, et al. At what price? A cost-
effectiveness analysis comparing trial of labour after previous caesarean
versus elective repeat caesarean delivery. PLoS ONE 2013;8:e58577.
[7] Grobman WA, Peaceman AM, Socol ML. Cost-effectiveness of elective
cesarean delivery after one prior low transverse cesarean. Obstet
Gynecol 2000;95:745–51.
[8] Pare E, Quinones JN, Macones GA. Vaginal birth after caesarean section
versus elective repeat caesarean section: assessment of maternal
downstream health outcomes. BJOG 2006;113:75–85.
[9] Gold MR, Siegel JE, Russell LB, et al., for the Panel on Cost-Effectiveness
in Health and Medicine. Cost-Effectiveness in Health and Medicine.
New York: Oxford University Press, 1996:6.
[10] Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-
adjusted life-year: in search of a standard. Med Decis Making 2000;20:332–42.
[11] Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal
outcomes associated with a trial of labor after prior cesarean delivery.
N Engl J Med 2004;351:2581–9.
[12] Spong CY, Landon MB, Gilbert S, et al. Risk of uterine rupture and
adverse perinatal outcome at term after cesarean delivery. Obstet
Gynecol 2007;110:801–7.
[13] American College of Obstetricians and Gynecologists. ACOG committee
opinion no. 394: cesarean delivery on maternal request. Obstet Gynecol
2007;110:1501–14.
[14] ACOG Committee on Practice Bulletins – Obstetrics. ACOG Practice
Bulletin No. 107: induction of labor. Obstet Gynecol 2009;114:
386–97.[15] Grobman WA, Gilbert S, Landon MB, et al. Outcomes of induction of
labor after one prior cesarean. Obstet Gynecol 2007;109:262–9.
[16] Martinez G, Daniels K, Chandra A. Fertility of men and women aged 15-
44 years in the United States: National Survey of Family Growth, 2006-
2010. In: National Health Statistics Reports (No. 51). Hyattsville, MD:
National Center for Health Statistics, 2012.
[17] Arias E. United States life tables, 2007. In: National Vital Statistics Reports
(Vol. 59, No. 9). Hyattsville, MD: National Center for Health Statistics, 2011.
[18] Press JZ, Klein MC, Kaczorowski J, et al. Does cesarean section reduce
postpartum urinary incontinence? A systematic review. Birth
2007;34:228–37.
[19] Simpson EL, Lawrenson RA, Nightingale AL, et al. Venous
thromboembolism in pregnancy and the puerperium: incidence and
additional risk factors from a London perinatal database. BJOG
2001;108:56–60.
[20] Casella G. Reﬁning binomial conﬁdence intervals. Can J Stat
1986;14:113–29.
[21] Guise J-M, McDonagh M, Hashima J, et al. Vaginal Birth After Cesarean
(VBAC). Evidence Report/Technology Assessment No. 71 (Prepared by
the Oregon Health & Science University Evidence-based Practice Center
under Contract No. 290-97-0018. AHRQ Publication No. 03-E018).
Rockville, MD: Agency for Healthcare Research and Quality, 2003.
[22] Baldawi N, Felix JF, Kurinczuk JJ, et al. Cerebral palsy following term
newborn encephalopathy: a population-based study. Dev Med Child
Neurol 2005;47:293–8.
[23] HCUPnet. Healthcare Cost and Utilization Project. Available from:
http://hcupnet.ahrq.gov/. [Accessed July 7, 2011].
[24] American Medical Association. CPT code/relative value search. Available
from: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp. [Accessed
September 28, 2010].
[25] United States Department of Labor, Bureau of Labor Statistics. Usual
weekly earnings of wage and salary workers. Available from: http://
www.bls.gov/cps/cpswktabs.htm. [Accessed July 7, 2011].
[26] Centers for Disease Control and Prevention. Economic costs associated
with mental retardation, cerebral palsy, hearing loss, and vision
impairment-United States, 2003. MMWR Morb Mortal Wkly Rep
2004;53:57–9.
[27] Katz RT. Life expectancy for children with cerebral palsy and mental
retardation: implications for life care planning. Neurorehabilitation
2003;18:261–70.
[28] Cerebral Palsy Source. Cerebral palsy quick facts. Available from: http://
www.cerebralpalsysource.com/About_CP/life_cp/index.html. [Accessed
October 25, 2009].
[29] Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary
incontinence. Obstet Gynecol 2001;98:398–406.
[30] United States Department of Labor, Bureau of Labor Statistics.
Consumer Price Index Report. Available from: http://www.bls.gov/cpi/.
[Accessed July 7, 2011].
[31] Haddox AC, Teutsch SM, Corso PS. Prevention Effectiveness: A Guide to
Decision Analysis and Economic Evaluation. New York: Oxford
University Press, 2003.
[32] Harris RA, Washington AE, Nease RF, et al. Cost utility of prenatal
diagnosis and the risk-based threshold. Lancet 2004;363:276–82.
[33] Manca A, Sculpher MJ, Ward K, et al. A cost-utility analysis of tension-
free vaginal tape versus colposuspension for primary urodynamic
stress incontinence. BJOG 2003;110:255–62.
[34] Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn
screening strategies. Pediatrics 2006;117(Suppl.):S287–95.
[35] Gold MR, Siegel JE, Russell LB, et al., for the Panel on Cost-Effectiveness
in Health and Medicine. Cost-Effectiveness in Health and Medicine.
New York: Oxford University Press, 1996:233.
[36] O’Shea MT, Klebanoff MA, Signore C. Delivery after a previous cesarean:
long-term outcomes in the child. Semin Perinatol 2010;34:281–92.
[37] National Institutes of Health Consensus Development Conference
Statement. Vaginal Birth After Cesarean: New Insights, March 8-10,
2010. Obstet Gynecol 2010;115:1279–95.
[38] Lewis RM, McKoy JN, Andrews JC, et al. Future Research Needs to
Reduce Cesarean Birth in Low-Risk Women. Future Research Needs
Paper No. 22 (Prepared by the Vanderbilt Evidence-based Practice
Center under Contract No. 290-2207-1065-I. AHRQ Publication No.
12(13)-EHC131-EF). Rockville, MD: Agency for Healthcare Research and
Quality, 2012.
